TrueTicker

NIFTY 500 › Chemicals

Chemicals · NIFTY 500

Privi Speciality Chemicals Ltd.

PRIVISCL on NSE · 19 Nov 2026

NIFTY 500

3,535.00 ▲ +2.81 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance

Filings

45 filings of PRIVISCL since November 2024; the newest 40 below.

board outcome 17, presentation 8, transcript 8, credit rating 4, dividend 3, scheme 3

FiledTypeSubject
03 Nov 2026transcript
Capex, Dividend / buy-back, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Transcript
AI summary

Transcript of the Q2 and H1 FY27 earnings conference call held October 30, 2026 on Privi Speciality Chemicals' unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026.

Management said Q2 total income was INR773.16 crores (up 13.9% YoY), EBITDA INR212.49 crores (up 16.66%) and PAT INR117.03 crores (up 24.61%), described as the highest ever quarterly sales and profitability.

Management declared the company's first ever interim dividend of INR5 per share (face value INR10) for FY27.

Management reiterated its expectation of maintaining about 20% overall growth in coming years and said Phase 1 capacity expansion (48,000 to 54,000 metric tons per annum) was completed as of September 30, 2026.

Management said net debt was INR814.51 crores, net debt to EBITDA 1.07x, ROCE 24.30%, and that state incentives of about INR12-15 crores are expected in the next two quarters.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Oct 2026presentation
Capex, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Investor Presentation
AI summary

Privi Speciality Chemicals filed its investor presentation on Q2 and H1 FY27 (quarter and half year ended September 30, 2026) with the stock exchanges.

Q2 FY27 consolidated total income Rs 773.16 Cr (up 13.9% YoY), EBITDA Rs 212.49 Cr (up 16.7% YoY, margin 27.48%), and PAT attributable to the company Rs 117.03 Cr (up 24.6% YoY).

H1 FY27 consolidated total income Rs 1,454.59 Cr (up 16.7% YoY), EBITDA Rs 379.96 Cr (up 17.6% YoY), and PAT attributable to the company Rs 201.23 Cr (up 29.1% YoY).

Management said the expansion projects are progressing as planned and will be ready for commercial operations in the second half of 2028.

Management said the company remains well positioned, citing a strong balance sheet, healthy cash flows and a clear strategic roadmap.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Oct 2026dividend
Acquisition, Capex, Dividend / buy-back, Results
Privi Speciality Chemicals Limited has informed the Exchange that Board of Directors at its meeting held on October 29, 2026, declared Interim Dividend of Rs. 05 per equity share.
AI summary

Board of Privi Speciality Chemicals Limited approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with limited review report from BSR & Co. LLP.

Board declared a first interim dividend of Rs. 5 per equity share (face value Rs. 10) for FY 2026-27; record date November 04, 2026; payment on or before November 25, 2026.

Board approved an investment limit of Rs. 2,97,00,000 in one or more tranches in Opera Dwarka Projects Private Limited for a Wind Solar Hybrid project at Gujarat for Unit VI; the company will make further disclosure on definitive agreements and actual investment.

Board meeting held 11:45 a.m. to 12:55 p.m. on October 29, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Oct 2026board outcome
Acquisition, Capex, Dividend / buy-back, Results
Privi Speciality Chemicals Limited has submitted to the Exchange, the outcome of the Board Meeting held on October 29,2026.
AI summary

Privi Speciality Chemicals Limited filed the outcome of its board meeting held on October 29, 2026.

The board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with a limited review report from BSR & Co. LLP.

The board declared a first interim dividend of Rs. 5 per equity share (face value Rs. 10) for FY 2026-27, with record date November 4, 2026 and payment on or before November 25, 2026.

The board approved an investment limit of Rs. 2,97,00,000 in one or more tranches in Opera Dwarka Projects Private Limited for a Wind Solar Hybrid project at Gujarat for Unit VI; the company will make further disclosures on execution of definitive agreements.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Aug 2026transcript
Acquisition, Capex, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Transcript of Earning Call held on Friday 31 July 2026.
AI summary

Privi Speciality Chemicals filed the transcript of its Q1 FY27 analyst/investors call held on July 30-31, 2026, on the quarter ended June 30, 2026.

Management said consolidated total income was about Rs. 681.42 crore (up 20.01% YoY), EBITDA Rs. 167.47 crore (up 18.73% YoY) at about 24.58% margin, and PAT about Rs. 83.2 crore versus Rs. 61.46 crore in Q1 FY26.

Management said Phase-1 capacity expansion (48,000 to 54,000 metric tons) is expected to be commercialised shortly, and the 6,000 MT tranche slipped from June 2026 to September 2026; Phase-2 (to 66,000 MT) is expected by September 2027.

Management reiterated the guidance of Rs. 5,000 crore revenue and Rs. 1,000 crore-plus EBITDA over three to four years, and said the proposed merger of Privi Speciality Chemicals, Privi Fine Sciences and Privi Biotechnologies has been filed with NCLT, with completion expected in this financial year.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jul 2026presentation
Capex, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Investor Presentation
AI summary

Privi Speciality Chemicals filed its investor presentation on financial and operational review for the quarter ended June 30, 2026 (Q1 FY27), ahead of an earnings call on July 31, 2026.

Management reported total income of Rs 681.42 Cr, up 20.01% year-on-year, and EBITDA of Rs 167.47 Cr, up 18.73% year-on-year, with an EBITDA margin of 24.58%.

Net profit (PAT attributable to the company) was Rs 84.21 Cr, up 35.97% year-on-year.

Management said an export consignment worth Rs 2.78 cr caught fire at a CFS warehouse near JNPT; an insurance claim has been filed and the company is confident of receiving it.

Management said the expansion projects are progressing as planned and will be ready for commercial operations in the second half of 2028.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jul 2026board outcome
Acquisition, Dividend / buy-back, Results
Privi Speciality Chemicals Limited has submitted to the Exchange, the Unaudited financial results for the period ended Jun 30, 2026.
AI summary

Privi Speciality Chemicals Limited's board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 at a meeting held on July 30, 2026, with an unmodified limited review conclusion from the statutory auditors.

The board recommended a final dividend of Rs. 10 per equity share (face value Rs. 10) for FY ended March 31, 2026, aggregating Rs. 3,906.27 lakhs, subject to shareholder approval at the ensuing AGM.

The Scheme of Amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with the company was filed before the NCLT Mumbai Bench on June 25, 2026, after observation letters from NSE and BSE in May 2026.

The filing does not state the revenue or profit figures for the quarter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jun 2026credit rating
Rating
Privi Speciality Chemicals Limited has informed the Exchange about Credit Rating- New
AI summary

Privi Speciality Chemicals Limited filed intimation under Regulation 30(6) of the SEBI LODR Regulations, 2015, reporting credit ratings.

ICRA Limited assigned a long-term rating of AA with Stable outlook.

The rated facility is a long-term fund-based term loan of Rs. 300 crores availed from ICICI Bank Limited.

ICRA's rating letter dated June 30, 2026 is enclosed.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jun 2026credit rating
Rating
Privi Speciality Chemicals Limited has informed the Exchange about Credit Rating- New
AI summary

Privi Speciality Chemicals Limited filed intimation under Regulation 30(6) of SEBI LODR regarding credit ratings.

ICRA Limited has assigned a long-term rating of AA, Outlook: Stable, to the Rs. 300 crore long-term fund-based term loan availed from ICICI Bank Limited.

The rating action is shown as "Assigned"; the ICRA rating letter dated June 30, 2026 is enclosed with the filing.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
15 May 2026transcript
Acquisition, Capex, Dividend / buy-back, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Transcript
AI summary

Privi Speciality Chemicals filed the transcript of its Q4 and FY26 earnings call held on May 12, 2026.

Management (Chairman Mahesh Babani, CFO Narayan S. Iyer) reported Q4 FY26 total income of INR725.70 crore (up 15.29% YoY), EBITDA of INR184.41 crore (up 25.09%), EBITDA margin of 25.41% and PAT of INR95.66 crore versus INR63.57 crore in Q4 FY25.

For FY26, management reported total income of INR2,582.92 crore (up 21.73%), EBITDA of INR665.45 crore (up 40.35%), EBITDA margin of 25.76% and PAT of INR327.54 crore (up 75.16%), with a Board-recommended dividend of INR10 per share.

Management said the first phase of capex is expected to be completed by June 30, 2026, taking installed capacity to 54,000 metric tons per annum, and that the proposed merger scheme has received no-objection observation letters from BSE and NSE and is to be filed with NCLT, with approval expected in FY27.

Management expects 20% growth and EBITDA margins of 20% plus going forward.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 May 2026presentation
Capex, Results
Privi Speciality Chemicals Limited has informed the Exchange about Investor Presentation
AI summary

Privi Speciality Chemicals filed its Investor Presentation on Financial & Operational Review for Q4 and FY ended March 31, 2026, ahead of an earnings call on May 12, 2026 at 4:00 pm IST.

Consolidated total income for FY26 was Rs. 2,582.92 crore, up 21.7% YoY; Q4 FY26 total income was Rs. 725.70 crore, up 15.5% YoY.

Consolidated EBITDA for FY26 was Rs. 665.45 crore (25.8% margin) versus Rs. 474.16 crore in FY25; Q4 FY26 EBITDA was Rs. 184.41 crore (25.4% margin).

Consolidated PAT attributable to the company was Rs. 327.54 crore for FY26, up 75.2% YoY, and Rs. 93.70 crore for Q4 FY26, up 40.9% YoY.

Management (Chairman & MD Mahesh Babani) said FY26 reflected strong execution, with operating cash flow of Rs. 550 crore, capex of Rs. 320 crore, and total debt reduced by Rs. 113 crore.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 May 2026dividend
Dividend / buy-back, Management change, Results
Privi Speciality Chemicals Limited has informed the Exchange that Board of Directors at its meeting held on May 11, 2026, recommended Final Dividend of Rs. 10 per equity share.
AI summary

Board of Privi Speciality Chemicals Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held May 11, 2026.

Board recommended a final dividend of Rs. 10 per equity share of Rs. 10 each (100%) for FY 2025-26, subject to shareholder approval at the 41st AGM on August 7, 2026.

Record date for the dividend is July 31, 2026; dividend, if approved, to be paid within 30 days of the AGM.

Board recommended re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as Executive (Whole-time) Director for 3 years from August 13, 2026 to August 12, 2029, subject to shareholder approval.

Board also approved re-appointment of M/s Aneja Associates as Internal Auditor for FY 2026-27 and M/s Kishore Bhatia & Associates as Cost Auditors for FY 2026-27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 May 2026board outcome
Dividend / buy-back, Management change, Results
Privi Speciality Chemicals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Board meeting held on May 11, 2026 approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with the statutory auditor's report enclosed.

Board recommended a final dividend of Rs. 10/- (100%) per equity share of Rs. 10/- each for FY 2025-26, subject to shareholder approval at the 41st AGM on August 7, 2026; record date is July 31, 2026.

Board approved re-appointment of Mr. Bhaktavatsala Rao Doppalapudi (DIN 00356218) as Executive Director (Whole-time Director) for 3 years from August 13, 2026 to August 12, 2029, subject to shareholder approval.

Board approved re-appointment of M/s. Aneja Associates as Internal Auditor for FY 2026-27 and M/s. Kishore Bhatia & Associates as Cost Auditors for FY 2026-27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 May 2026scheme
Acquisition, Legal
Privi Speciality Chemicals Limited has informed the Exchange regarding receipt of observation letter from BSE Limited in relation to Scheme of amalagamation between Privi Speciality Chemicals Limited ( Transferee Company/PSCL ), Privi Fine
AI summary

Privi Speciality Chemicals Limited filed an intimation under SEBI LODR Regulation 30 on receipt of an observation letter with 'no objection' from BSE Limited, dated May 06, 2026, on the proposed scheme of amalgamation.

The scheme merges Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited into Privi Speciality Chemicals Limited under sections 230 to 232 of the Companies Act, 2013.

The Board had approved the scheme earlier, with an intimation dated December 19, 2025, subject to regulatory and statutory approvals.

The company stated that the scheme remains subject to applicable regulatory and other approvals.

The observation letter is also hosted on the company's website.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 May 2026scheme
Acquisition, Legal
Privi Speciality Chemicals Limited has informed the Exchange about Receipt of Observation Letters from National Stock Exchange of India Limited in relation to the scheme of amalgamation between Privi Speciality Chemicals Limited ( Transfere
AI summary

Privi Speciality Chemicals Limited intimated that it has received an observation letter with "no objection" from the National Stock Exchange of India Limited, dated May 2026 (day garbled in OCR), on the proposed scheme of amalgamation with Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited under sections 230 to 232 of the Companies Act, 2013.

The observation letter from BSE is awaited.

The scheme remains subject to applicable regulatory and other approvals.

This follows the Board approval of the scheme intimated earlier on December 19, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
21 Apr 2026credit rating
Rating
Privi Speciality Chemicals Limited has informed the Exchange about Credit Rating
AI summary

Privi Speciality Chemicals Limited filed intimation under Regulation 30(6) of SEBI LODR on the rating action by CRISIL Ratings Limited.

CRISIL reaffirmed the long-term rating at AA-/Stable on the bank facilities.

CRISIL reaffirmed the short-term rating at A1+ on the bank facilities.

Total bank loan facilities rated are Rs.1,118 crore, per CRISIL's letter dated April 21, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
16 Feb 2026transcript
Acquisition, Capex, Dividend / buy-back, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Transcript
AI summary

Transcript of the Q3 and 9M FY26 earnings conference call of Privi Speciality Chemicals held on February 10, 2026, filed with BSE and NSE.

Management said Q3 total income was INR611.15 crores, up 25% year-on-year, with EBITDA of INR158 crores (25.83% margin), up 37%; PAT adjusted for a one-time Labour Code impact and non-controlling interest was about INR82 crores versus INR44 crores a year earlier.

For 9M FY26, management reported total income of INR1,857 crores (up about 24%), EBITDA of INR481 crores (up about 47%) and PAT of about INR232 crores (up about 84%).

Management guided to EBITDA margins sustaining above 20%, about 7% volume growth in the coming financial year (later indicated as 11% to 15%), and a long-term vision of INR5,000 crores revenue and EBITDA above INR1,000 crores in 3 to 4 years.

Management said capacity expansion from 48,000 to 54,000 metric tons is expected to be commercialised by end-March or April 2026, and about INR1,200 crores of capex is planned over three phases to about FY28; the debt-to-EBITDA guideline is below 2.5x (currently about 1.6x).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Feb 2026presentation
Acquisition, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Investor Presentation
AI summary

Privi Speciality Chemicals filed its investor presentation on financial and operational review for the quarter and nine months ended December 31, 2025, following an earnings call on February 10, 2026.

Consolidated Q3 FY26 revenue from operations was Rs. 604.64 crore (Rs. 490.87 crore in Q3 FY25); total income was Rs. 611.15 crore, up 24% YoY; EBITDA was Rs. 157.85 crore, up 37% YoY, at a 25.83% margin; PAT attributable to the company was Rs. 77.99 crore, up 76% YoY.

Consolidated 9M FY26 total income was Rs. 1,857.23 crore, up 24% YoY; EBITDA was Rs. 481.04 crore, up 47% YoY, at a 25.90% margin; PAT attributable to the company was Rs. 233.84 crore, up 94% YoY.

The Chairman & Managing Director, Mr. Mahesh Babani, said the company delivered a healthy performance with 24% revenue growth on a YoY basis despite tariff-related uncertainties, and reiterated confidence in its long-term 5k:1k vision over the next 3–4 years.

Management also referred to a proposed Scheme of Amalgamation as a step toward operational consolidation.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
09 Feb 2026board outcome
Acquisition, Capex, Results
Privi Speciality Chemicals Limited has informed the Exchange regarding Board meeting held on February 09, 2026.
AI summary

Privi Speciality Chemicals Limited filed the outcome of its board meeting held on 9 February 2026 (the filing refers to 2025 in one place, but the meeting date is 9 February 2026).

The board approved and took on record the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with the statutory auditor's limited review report (BSR&Co. LLP).

The board approved an equity investment of Rs. 50 crores in Privi's subsidiary Prigiv Specialties Private Limited, in the existing 51:49 shareholding ratio: Privi to invest Rs. 25.5 crores (51%) and JV partner Givaudan SA the balance 49%.

The company stated the equity infusion will support Prigiv's growth plans, enabling higher revenue and improved profitability going forward.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
09 Feb 2026board outcome
Acquisition, Capex, Results
Privi Speciality Chemicals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Privi Speciality Chemicals filed the outcome of its board meeting held on 9 February 2026, which approved unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with a limited review report from statutory auditors BSR&Co.LLP.

The board approved an equity investment of Rs. 50 crores in its subsidiary Prigiv Specialties Private Limited, in the existing 51:49 shareholding ratio.

Privi will invest 51% of the total, amounting to Rs. 25.5 crores, and the 49% balance will be contributed by its JV partner Givaudan SA.

The company stated the equity infusion will support growth plans, enabling higher revenue and improved profitability going forward.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Dec 2025board outcome
Acquisition, Legal
Privi Speciality Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on December 19, 2025 to consider & Approve Scheme of Amalgamation
AI summary

The board of Privi Speciality Chemicals Limited, at its meeting held on December 19, 2025, approved a Scheme of Amalgamation under Sections 230 to 232 of the Companies Act, 2013.

The scheme provides for amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited (a wholly owned subsidiary) into Privi Speciality Chemicals Limited, without winding up of the transferor companies.

The scheme is subject to approval of shareholders, creditors, the National Company Law Tribunal and other regulatory authorities.

The transaction is stated to fall within related party transactions under SEBI LODR Regulations, and valuation was carried out by RBSA Valuation Advisors LLP with a fairness opinion from Vivro Financial Services Private Limited.

Half-year ended September 30, 2025 turnover of Privi Fine Sciences Private Limited was Rs. 240.00 lakhs (standalone), with net worth of Rs. 2,072.75 lakhs and total assets of Rs. 2,387.61 lakhs; figures for Privi Biotechnologies Private Limited were not clearly legible in the text.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Dec 2025board outcome
Acquisition, Legal
Privi Speciality Chemicals Limited has informed the Exchange regarding outcome of Board meeting held on December 19, 2025. inter alia approved Scheme of Amalgamation
AI summary

The Board of Privi Speciality Chemicals Limited, at its meeting held on December 19, 2025 (3:00 p.m. to 5:00 p.m.), approved a Scheme of Amalgamation under Sections 230 to 232 of the Companies Act, 2013.

The scheme provides for amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited (a wholly owned subsidiary) into Privi Speciality Chemicals Limited, with dissolution of the transferor companies without winding up.

The scheme is subject to approval of shareholders, creditors, the National Company Law Tribunal and other regulatory authorities.

Valuation was carried out by RBSA Valuation Advisors LLP, with a fairness opinion from Vivro Financial Services Private Limited.

The transaction is classed as a related party transaction under SEBI LODR Regulations; the company states it is on arm's length basis.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
15 Nov 2025board outcome
Acquisition, Legal
Privi Speciality Chemicals Limited has informed the Exchange regarding Board meeting held on November 15, 2025 - for withdrawal of application filed under Regulation 37 of SEBI (LODR) Regulations, 2015 for obtaining NOC from Stock Exchanges
AI summary

Privi Speciality Chemicals Limited filed the outcome of its board meeting held on November 15, 2025 (11:00 a.m. to 11:45 a.m.).

The board approved withdrawal of the Scheme of Amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with the company and their shareholders, filed under Sections 230 to 232 of the Companies Act, 2013.

The withdrawal was a voluntary board decision based on observations received from the stock exchanges.

The company proposes to refile the scheme shortly and states no adverse impact is expected from the withdrawal.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Nov 2025transcript
Capex, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Transcript
AI summary

Privi Speciality Chemicals filed the transcript of its Q2 and H1 FY'26 earnings conference call held on November 7, 2025, covering results for the quarter and half year ended September 30, 2025.

Management (CFO Narayan S. Iyer) said Q2 consolidated total income was Rs. 678.82 crores, up 26% year-on-year, with record EBITDA of Rs. 182.14 crores (59% growth) and EBITDA margin of 26.83%; Q2 profit after tax was Rs. 90.21 crores versus Rs. 44.84 crores a year earlier.

For H1 FY'26, management said total income was about Rs. 1,246.08 crores (24% growth), EBITDA Rs. 323.19 crores (53% growth, margin 25.94%) and profit after tax Rs. 147.76 crores (94% growth).

Management said net working capital cycle improved to 124 days from 136 days in March 2025, and net debt stood at Rs. 1,020 crores as on September 2025.

Management said Phase-1 capacity expansion will raise capacity from 48,000 to 54,000 metric tons, with the balance to be completed by end of FY'26, and reiterated a vision of Rs. 5,000 crores revenue and Rs. 1,000 crores EBITDA in three to four years; it expects EBITDA margin between 24% and 26%.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2025presentation
Acquisition, Capex, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Investor Presentation
AI summary

Privi Speciality Chemicals filed its investor presentation on financial and operational review for the quarter and half year ended September 30, 2025, with an earnings call scheduled for November 7, 2025 at 4:00 pm IST.

Consolidated revenue for Q2FY26 was Rs. 678.82 crore, up 26% YoY; EBITDA was Rs. 182.14 crore, up 59% YoY, with EBITDA margin of 26.83%; PAT was Rs. 90.21 crore, up 101% YoY.

For H1FY26, revenue was Rs. 1,246.08 crore, up 24% YoY; EBITDA was Rs. 323.19 crore, up 53% YoY, with EBITDA margin of 25.94%; PAT was Rs. 147.76 crore, up 94% YoY.

Management (CMD Mahesh Babani) described the results as the best-ever quarterly and half-yearly performance and said Phase I of the expansion has been partly completed, with the balance expected by December 2025.

Management also said a three-phase expansion roadmap over 3-4 years aims to enhance capacity by about 50%, and disclosed a proposed Scheme of Amalgamation of Privi Fine Sciences Private Limited, Privi Biotechnology Private Limited and Privi Speciality Chemicals Limited.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Nov 2025board outcome
Results
Privi Speciality Chemicals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Privi Speciality Chemicals Limited filed the outcome of its board meeting held on November 05, 2025, which approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025.

The statutory auditor BSR&Co.LLP issued a limited review report on the unaudited standalone results, stating nothing came to its attention that the statement had not disclosed required information or contained a material misstatement.

The filing attaches the standalone balance sheet as at September 30, 2025 and the standalone statement of results; the figures are in Rs lakhs, with the company's total income and profit lines shown in the attached tables.

The financial results are also available on the company's website, www.privi.com.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Nov 2025board outcome
Results
Privi Speciality Chemicals Limited has informed the Exchange regarding Board meeting held on November 05, 2025.
AI summary

Privi Speciality Chemicals Limited filed the outcome of its board meeting held on November 05, 2025, which approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025.

The statutory auditors (BSR&Co. LLP) issued a limited review report on the unaudited standalone results, with no matters reported that suggest material misstatement.

The filing states that the financial results and limited review report are enclosed and available on the company website, www.privi.com.

The OCR text of the financial tables is partly garbled, so the individual revenue and profit figures are not reliably stated here.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Aug 2025transcript
Acquisition, Capex, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Transcript
AI summary

Privi Speciality Chemicals filed the transcript of its Q1 FY'26 earnings call held on August 05, 2025, on the quarter ended June 30, 2025.

Management (Narayan S. Iyer, CFO) said consolidated income was about Rs. 568 crores, up about 22% year-on-year; consolidated EBITDA was about Rs. 141 crores (45% growth) at a 24.8% margin; consolidated profit after tax was about Rs. 61 crores versus Rs. 32 crores a year earlier.

Management (Mahesh Babani, Chairman & MD) said a scheme of amalgamation involving Privi Fine Sciences, Privi Biotechnologies and Privi Speciality Chemicals has been proposed, and cited a 5,000-1,000 vision of Rs. 5,000 crores revenue and Rs. 1,000 crores EBITDA in 3-5 years.

Management (Sanjeev Patil, SVP Strategy) said about 70% of business is contracted for the year, US exports are about 7% of revenue, and the 20% growth guidance is intact.

Management (Narayan S. Iyer) said capacity expansion is on track for completion by March 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Aug 2025presentation
Acquisition, Capex, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Investor Presentation
AI summary

Privi Speciality Chemicals filed its investor presentation on financial and operational review for the quarter ended June 30, 2025 (Q1 FY25-26), with an earnings call held on August 5, 2025 at 4:00 pm IST.

Standalone revenue from operations rose 29.6% to Rs 574.7 Cr and consolidated revenue rose 21.7% to Rs 567.8 Cr, year on year, driven mainly by higher sales of flagship and specialty products (Q1 FY24-25 standalone Rs 443.4 Cr).

Standalone EBITDA rose 50.4% to Rs 144.7 Cr and standalone PAT rose 113.3% to Rs 68.7 Cr; consolidated EBITDA rose 45.3% to Rs 141.1 Cr and consolidated PAT rose 97.1% to Rs 61.9 Cr.

Management said Prigiv, in its first year of operations, has not yet broken even, and its loss reduced consolidated profit.

Management said Phase 1 of the capacity expansion is partly complete and will contribute from Q2 FY26, with the project fully completed in Q4 FY26; the company also noted the proposed scheme of amalgamation of Privi Fine Sciences Limited, Privi Biotechnology Private Limited and Privi Speciality Chemicals Limited.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Aug 2025board outcome
Results
Privi Speciality Chemicals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Privi Speciality Chemicals Limited filed the outcome of its board meeting held on August 01, 2025, approving unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with the statutory auditors' limited review report (BSR&Co. LLP, dated 01 August 2025).

The filing encloses the standalone results statement; the figures are in Rs lakhs, with revenue from operations for the quarter ended June 30, 2025 shown as 56,635.59 (OCR-garbled, to be verified).

The auditors' limited review report found nothing to indicate the statement was not prepared per Ind AS 34 and Regulation 33, and drew attention to the Q4 FY25 figures being balancing figures.

The results are also posted on the company website, www.privi.com.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Aug 2025board outcome
Results
Privi Speciality Chemicals Limited has informed the Exchange regarding Board meeting held on August 01, 2025 for approval of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025.
AI summary

Privi Speciality Chemicals Limited filed the outcome of its board meeting held on August 1, 2025, which approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a limited review report from the statutory auditors (BSR & Co. LLP).

The standalone statement shows revenue from operations of Rs. 56,635.59 lakhs for the quarter ended June 30, 2025, compared with Rs. 58,072.85 lakhs in the quarter ended June 30, 2024 (figures as printed; OCR text is partly garbled).

The standalone results are in Rs. lakhs; the printed net profit and EPS figures are partly illegible in the OCR, so they are not stated here.

The results are also available on the company's website, www.privi.com.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Jun 2025scheme
Acquisition, Capex, Legal
Privi Speciality Chemicals Limited has informed the Exchange about approval of scheme of Amalgamation/Merger by Board of Directors in their meeting held on June 14, 2025
AI summary

Privi Speciality Chemicals Limited filed the outcome of its board meeting held on June 14, 2025 (meeting ran from 11:30 a.m. to 12:50 p.m.).

The board decided not to proceed with a qualified institutions placement of equity shares aggregating up to Rs 1,000 crores, citing improved performance and sufficient cash accruals to meet capex needs.

The board approved a scheme of amalgamation of Privi Fine Sciences Private Limited (related party) and Privi Biotechnologies Private Limited (wholly owned subsidiary) into the company under Sections 230 to 233 of the Companies Act, 2013, superseding the June 24, 2024 board resolution.

The scheme is a material related party transaction and is subject to shareholder approval, NCLT, SEBI, stock exchange and creditor approvals.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Jun 2025board outcome
Acquisition, Capex, Legal
Privi Speciality Chemicals Limited has informed the Exchange regarding Board meeting held on Jun 14, 2025.
AI summary

Board of Privi Speciality Chemicals Limited met on June 14, 2025 (11:30 a.m. to 12:50 p.m.) and decided not to proceed with the qualified institutions placement of equity shares aggregating up to Rs 1,000 crores, citing improved performance and sufficient cash accruals for capex.

The Board approved a scheme of amalgamation of Privi Fine Sciences Private Limited (PFSPL, a related party) and Privi Biotechnologies Private Limited (PBPL, a wholly owned subsidiary) into the company under Sections 230 to 233 of the Companies Act, 2013; this supersedes the board resolution dated June 24, 2024.

The scheme is a material related party transaction and is subject to shareholder approval, creditor approvals, NCLT, SEBI, and stock exchange approvals.

The valuation report and fairness opinion on the share exchange ratio are referenced in Annexure I, and PFSPL's audited net worth, assets and turnover are disclosed.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 May 2025transcript
Capex, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Transcript
AI summary

Privi Speciality Chemicals filed the transcript of its analyst/investor call held on May 6, 2025, on the audited standalone and consolidated results for Q4 and FY25 (quarter and year ended March 31, 2025).

Management said Q4 FY25 total income was a record Rs.628 crores (up 28% YoY), EBITDA Rs.147 crores (up 50% YoY) with a record EBITDA margin of 23.5%, and profit after tax Rs.64 crores versus Rs.32 crores a year earlier.

For FY25, management said total income was Rs.2,122 crores (up 19%), EBITDA Rs.474 crores (up about 37%, margin 22.3% vs 19.7%), and profit after tax Rs.185 crores versus Rs.95 crores.

Management said it expects to keep EBITDA margins north of 20% and aims for average growth of 20% to 25%, while not giving formal forward guidance; it said capacity is being expanded from 48,000 to 54,000 metric tons by March 2026.

Management said the PRIGIV JV plant was commissioned, started operations around February 2025, and is expected to break even around FY26-27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 May 2025presentation
Capex, Dividend / buy-back, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Investor Presentation
AI summary

Privi Speciality Chemicals filed its investor presentation on Q4 and FY25 financial and operational review, following an earnings call on May 6, 2025.

Management said Q4 FY25 was the highest-ever quarterly performance: consolidated total income Rs 628.37 crores (up 28% YoY), EBITDA Rs 147.42 crores (up 50%), PAT Rs 63.98 crores (up 101%).

For FY25, consolidated total income was Rs 2,121.84 crores (up 19%), EBITDA Rs 474.16 crores (up 35%), PAT Rs 184.75 crores (up 94%), with export sales at 70% of revenue.

The Board recommended a final dividend of Rs 5 per equity share of Rs 10 each (50%).

Management said the PRIGIV plant has been commissioned and capacity will be expanded by 6,000 MTPA through debottlenecking, expected to complete by end of FY26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 May 2025board outcome
Dividend / buy-back, Results
Privi Speciality Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 03, 2025.
AI summary

Privi Speciality Chemicals Limited filed the outcome of its board meeting held on May 03, 2025, which approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with an unmodified audit opinion from BSR & Co., LLP.

The board recommended a final dividend of Rs. 5 per equity share (50% on Rs. 10 face value) for FY 2024-25, subject to shareholder approval at the 40th Annual General Meeting on August 01, 2025; the record date is July 24, 2025.

The board approved re-appointment of BSR & Co., LLP as Statutory Auditors for a second term of five years, and appointment of Rathi & Associates as Secretarial Auditors for five years from FY 2025-26 to FY 2029-30, both subject to shareholder approval.

The register of members will be closed from July 25, 2025 to August 01, 2025 (both inclusive) for the AGM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 May 2025dividend
Dividend / buy-back, Management change, Results
Privi Speciality Chemicals Limited has informed the Exchange that Board of Directors at its meeting held on May 03, 2025, recommended Final Dividend of 5 per equity share.
AI summary

Privi Speciality Chemicals Limited filed the outcome of its board meeting held on May 3, 2025, approving audited standalone and consolidated financial results for the quarter and year ended March 31, 2025.

The board recommended a final dividend of Rs. 5/- (50%) per equity share of Rs. 10/- each for FY2024-25, subject to shareholder approval at the 40th Annual General Meeting.

The board approved re-appointment of BSR & Co., LLP as statutory auditors for a second term of five years, and appointment of Rathi & Associates as secretarial auditors for five years from FY2025-26, both subject to shareholder approval.

The record date for the dividend is Thursday, July 24, 2025; the 40th AGM is scheduled for August 1, 2025, with the register of members closed from July 25 to August 1, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 May 2025board outcome
Dividend / buy-back, Results
Privi Speciality Chemicals Limited has informed the Exchange regarding Board meeting held on May 03, 2025.
AI summary

Privi Speciality Chemicals Limited filed the outcome of its board meeting held on May 03, 2025, which approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with an unmodified audit opinion from BSR & Co., LLP.

The board recommended a final dividend of Rs. 5 per equity share (50% on Rs. 10 face value), subject to shareholder approval at the 40th Annual General Meeting on August 01, 2025; record date is July 24, 2025.

The board approved re-appointment of BSR & Co., LLP as statutory auditors for a second term of five years, and appointment of Rathi & Associates as secretarial auditors for five years from FY 2025-26, both subject to shareholder approval.

The register of members will be closed from July 25, 2025 to August 01, 2025 (both inclusive) for the AGM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Mar 2025credit rating
Rating
Privi Speciality Chemicals Limited has informed the Exchange about Credit Rating- Revision
AI summary

Privi Speciality Chemicals Limited filed intimation under SEBI LODR Regulation 30(6) of a rating revision by CRISIL Ratings Limited, dated March 10, 2025.

Long-term rating upgraded from Crisil A+/Positive to Crisil AA-/Stable; short-term rating upgraded from Crisil A1 to Crisil A1+.

Total bank loan facilities rated are Rs. 1118 crore across fund-based, non-fund based and term loan facilities from multiple banks.

The rating letter remains valid till March 31, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 Feb 2025transcript
Capex, Guidance, Results
Privi Speciality Chemicals Limited has informed the Exchange about Transcript
AI summary

Privi Specialty Chemicals filed the transcript of its Q3 FY25 earnings conference call held on February 13, 2025, covering results for the quarter ended December 31, 2024.

Management said Q3 total income was about INR493 crores with EBITDA of about INR115 crores (margin about 23%) and profit after tax of about INR44 crores versus INR29 crores a year earlier; exports were 69% of revenue.

For the nine months, total income was about INR1,493 crores (up about 16%), EBITDA about INR327 crores (up about 29%, margin 21.9%) and profit after tax about INR121 crores versus INR63 crores.

Management said it expects at least 20% revenue growth in FY25-26, with about 70% of business contracted, and price increases of about 7% to 10% across products from Q4.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in